Pharmaceutical co-crystal compositions and related methods of use

A pharmaceutical co-crystal comprising:

• a) a stavudine:melamine co-crystal, wherein said stavudine:melamine co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks at 11.06, 22.40, and 24.64 degrees 2-theta;
• b) a stavudine:melamine co-crystal, wherein said stavudine:melamine co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks at 11.06, 18.32, and 20.24 degrees 2-theta;
• c) a stavudine:melamine co-crystal, wherein said stavudine:melamine co-crystal is characterized by a powder X-ray diffraction pattern that is substantially as shown in FIG. 18;
• d) a stavudine:melamine co-crystal, wherein said stavudine:melarnine co-crystal is characterized by an IR spectrum comprising peaks at 1655, 1446, and 799 cm−1;
• e) a stavudine:melamine co-crystal, wherein said stavudine:melamine co-crystal is characterized by an IR spectrum comprising peaks at 1542, 1268, and 1091 cm−1;
• f) a stavudine :2-aminopyridine co-crystal, wherein said stavudine:2-aminopyridine co-crystal is characterized by an IR spectrum comprising peaks at 1698, 1433, and 1075 cm−1;
• g) a stavudine:2-aminopyridine co-crystal, wherein said stavudine:2-aminopyridine co-crystal is characterized by an IR spectrum comprising peaks at 1666, 1221, and 974 cm−1;
• h) a stavudine:2-aminopyridine co-crystal, wherein said stavudine:2-aminopyridine co-crystal is characterized by an IR spectrum comprising peaks at 1698, 1666, and 1629 cm−1;
• or
• i) a stavudine:2-aminopyridine co-crystal, wherein said stavudine:2-aminopyridine co-crystal is characterized by IR spectrum that is substantially as shown in FIG. 20A.